{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T08:14:27Z","timestamp":1790583267037,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI145435-A1"],"award-info":[{"award-number":["R01-AI145435-A1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI153349"],"award-info":[{"award-number":["R01-AI153349"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21- AI149760"],"award-info":[{"award-number":["R21- AI149760"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K08-AI139371"],"award-info":[{"award-number":["K08-AI139371"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01-HL131829"],"award-info":[{"award-number":["R01-HL131829"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pretomanid is a nitroimidazole antimicrobial active against drug-resistant\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    and approved in combination with bedaquiline and linezolid (BPaL) to treat multidrug-resistant (MDR) pulmonary tuberculosis (TB). However, the penetration of these antibiotics into the central nervous system (CNS), and the efficacy of the BPaL regimen for TB meningitis, are not well established. Importantly, there is a lack of efficacious treatments for TB meningitis due to MDR strains, resulting in high mortality. We have developed new methods to synthesize\n                    <jats:sup>18<\/jats:sup>\n                    F-pretomanid (chemically identical to the antibiotic) and performed cross-species positron emission tomography (PET) imaging to noninvasively measure pretomanid concentration-time profiles. Dynamic PET in mouse and rabbit models of TB meningitis demonstrates excellent CNS penetration of pretomanid but cerebrospinal fluid (CSF) levels does not correlate with those in the brain parenchyma. The bactericidal activity of the BPaL regimen in the mouse model of TB meningitis is substantially inferior to the standard TB regimen, likely due to restricted penetration of bedaquiline and linezolid into the brain parenchyma. Finally, first-in-human dynamic\n                    <jats:sup>18<\/jats:sup>\n                    F-pretomanid PET in six healthy volunteers demonstrates excellent CNS penetration of pretomanid, with significantly higher levels in the brain parenchyma than in CSF. These data have important implications for developing new antibiotic treatments for TB meningitis.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-35730-3","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T08:08:24Z","timestamp":1672301304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Dynamic 18F-Pretomanid PET imaging in animal models of TB meningitis and human studies"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-0778","authenticated-orcid":false,"given":"Filipa","family":"Mota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo A.","family":"Ruiz-Bedoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0971-3635","authenticated-orcid":false,"given":"Elizabeth W.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7606-9069","authenticated-orcid":false,"given":"Patricia","family":"De Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Lodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Erice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1574-7759","authenticated-orcid":false,"given":"Xueyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0278-000X","authenticated-orcid":false,"given":"Melissa","family":"Bahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Flavahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-5916","authenticated-orcid":false,"given":"John","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Katherine","family":"Brosnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-0655","authenticated-orcid":false,"given":"Alvaro A.","family":"Ordonez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Dannals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-7070","authenticated-orcid":false,"given":"Sanjay K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"35730_CR1","unstructured":"WHO. Global tuberculosis report. Geneva: World Health Organization (2022)."},{"key":"35730_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41590-018-0119-x","volume":"19","author":"SK Jain","year":"2018","unstructured":"Jain, S. K. et al. Tuberculous meningitis: a roadmap for advancing basic and translational research. Nat. Immunol. 19, 521\u2013525 (2018).","journal-title":"Nat. Immunol."},{"key":"35730_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrneurol.2017.120","volume":"13","author":"RJ Wilkinson","year":"2017","unstructured":"Wilkinson, R. J. et al. Tuberculous meningitis. Nat. Rev. Neurol. 13, 581\u2013598 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"35730_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S1473-3099(14)70852-7","volume":"14","author":"SS Chiang","year":"2014","unstructured":"Chiang, S. S. et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect. Dis. 14, 947\u2013957 (2014).","journal-title":"Lancet Infect. Dis."},{"key":"35730_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1086\/430616","volume":"192","author":"GE Thwaites","year":"2005","unstructured":"Thwaites, G. E. et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J. Infect. Dis. 192, 79\u201388 (2005).","journal-title":"J. Infect. Dis."},{"key":"35730_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12941-015-0107-z","volume":"14","author":"S Senbayrak","year":"2015","unstructured":"Senbayrak, S. et al. Antituberculosis drug resistance patterns in adults with tuberculous meningitis: results of haydarpasa-iv study. Ann. Clin. Microbiol Antimicrob. 14, 47 (2015).","journal-title":"Ann. Clin. Microbiol Antimicrob."},{"key":"35730_CR7","first-page":"401","volume":"64","author":"C Vinnard","year":"2017","unstructured":"Vinnard, C. et al. Long-term mortality of patients with tuberculous meningitis in New York City: a cohort study. Clin. Infect. Dis. 64, 401\u2013407 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"35730_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/cid\/cix230","volume":"65","author":"AD Heemskerk","year":"2017","unstructured":"Heemskerk, A. D. et al. Clinical outcomes of patients with drug-resistant tuberculous meningitis treated with an intensified antituberculosis regimen. Clin. Infect. Dis. 65, 20\u201328 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"35730_CR9","doi-asserted-by":"publisher","first-page":"e0270201","DOI":"10.1371\/journal.pone.0270201","volume":"17","author":"EE Evans","year":"2022","unstructured":"Evans, E. E. et al. Long term outcomes of patients with tuberculous meningitis: the impact of drug resistance. PLoS One 17, e0270201 (2022).","journal-title":"PLoS One"},{"key":"35730_CR10","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","volume":"79","author":"SJ Keam","year":"2019","unstructured":"Keam, S. J. Pretomanid: first approval. Drugs 79, 1797\u20131803 (2019).","journal-title":"Drugs"},{"key":"35730_CR11","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/35016103","volume":"405","author":"CK Stover","year":"2000","unstructured":"Stover, C. K. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962\u2013966 (2000).","journal-title":"Nature"},{"key":"35730_CR12","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1126\/science.1164571","volume":"322","author":"R Singh","year":"2008","unstructured":"Singh, R. et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322, 1392\u20131395 (2008).","journal-title":"Science"},{"key":"35730_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1476-5381.2010.01040.x","volume":"162","author":"M Dogra","year":"2011","unstructured":"Dogra, M. et al. Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in mycobacteria and a subcellular fraction of human liver. Br. J. Pharm. 162, 226\u2013236 (2011).","journal-title":"Br. J. Pharm."},{"key":"35730_CR14","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1128\/AAC.49.6.2294-2301.2005","volume":"49","author":"AJ Lenaerts","year":"2005","unstructured":"Lenaerts, A. J. et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49, 2294\u20132301 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"35730_CR15","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1128\/AAC.48.5.1441-1453.2004","volume":"48","author":"M Muller","year":"2004","unstructured":"Muller, M., dela Pena, A. & Derendorf, H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob. Agents Chemother. 48, 1441\u20131453 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"35730_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41591-020-0770-2","volume":"26","author":"AA Ordonez","year":"2020","unstructured":"Ordonez, A. A. et al. Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. Nat. Med. 26, 529\u2013534 (2020).","journal-title":"Nat. Med."},{"key":"35730_CR17","doi-asserted-by":"publisher","first-page":"eaau0965","DOI":"10.1126\/scitranslmed.aau0965","volume":"10","author":"EW Tucker","year":"2018","unstructured":"Tucker, E. W. et al. Noninvasive (11)C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis. Sci. Transl. Med. 10, eaau0965 (2018).","journal-title":"Sci. Transl. Med."},{"key":"35730_CR18","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1021\/acsinfecdis.9b00473","volume":"6","author":"F Mota","year":"2020","unstructured":"Mota, F. et al. Radiosynthesis and biodistribution of (18)F-Linezolid in mycobacterium tuberculosis-infected mice using positron emission tomography. ACS Infect. Dis. 6, 916\u2013921 (2020).","journal-title":"ACS Infect. Dis."},{"key":"35730_CR19","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1242\/dmm.027326","volume":"9","author":"EW Tucker","year":"2016","unstructured":"Tucker, E. W. et al. Microglia activation in a pediatric rabbit model of tuberculous meningitis. Dis. Model Mech. 9, 1497\u20131506 (2016).","journal-title":"Dis. Model Mech."},{"key":"35730_CR20","doi-asserted-by":"crossref","unstructured":"Ruiz-Bedoya, C. A. et al. High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis. J. Clin. Invest. 132, 1\u201311 (2022).","DOI":"10.1172\/JCI155851"},{"key":"35730_CR21","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1002\/ange.201504665","volume":"127","author":"T Khotavivattana","year":"2015","unstructured":"Khotavivattana, T. et al. 18F\u2010Labeling of Aryl\u2010SCF3,\u2010OCF3 and\u2010OCHF2 with [18F] Fluoride. Angew. Chem. 127, 10129\u201310133 (2015).","journal-title":"Angew. Chem."},{"key":"35730_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1128\/AAC.00849-10","volume":"55","author":"Z Ahmad","year":"2011","unstructured":"Ahmad, Z. et al. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55, 239\u2013245 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"35730_CR23","unstructured":"European Medicines Agency. Pretomanid FGK, Assessment report. European Medicines Agency (2020)."},{"key":"35730_CR24","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1056\/NEJMoa040573","volume":"351","author":"GE Thwaites","year":"2004","unstructured":"Thwaites, G. E. et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N. Engl. J. Med. 351, 1741\u20131751 (2004).","journal-title":"N. Engl. J. Med."},{"key":"35730_CR25","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1021\/acsinfecdis.9b00207","volume":"5","author":"AA Ordonez","year":"2019","unstructured":"Ordonez, A. A. et al. Radiosynthesis and PET bioimaging of (76)Br-bedaquiline in a murine model of tuberculosis. ACS Infect. Dis. 5, 1996\u20132002 (2019).","journal-title":"ACS Infect. Dis."},{"key":"35730_CR26","unstructured":"WHO. Ten threats to global health. https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in-2019 (2019)."},{"key":"35730_CR27","doi-asserted-by":"crossref","unstructured":"Ordonez, A. A. et al. Visualizing the dynamics of tuberculosis pathology using molecular imaging. J. Clin. Invest. 131, 1\u201311 (2021).","DOI":"10.1172\/JCI145107"},{"key":"35730_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jchromb.2015.02.041","volume":"988","author":"D Bratkowska","year":"2015","unstructured":"Bratkowska, D. et al. Determination of the antitubercular drug PA-824 in rat plasma, lung and brain tissues by liquid chromatography tandem mass spectrometry: application to a pharmacokinetic study. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 988, 187\u2013194 (2015).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"35730_CR29","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1016\/S1473-3099(21)00122-5","volume":"22","author":"T Bjarnsholt","year":"2022","unstructured":"Bjarnsholt, T. et al. The importance of understanding the infectious microenvironment. Lancet Infect. Dis. 22, e88\u2013e92 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"35730_CR30","doi-asserted-by":"crossref","unstructured":"Xu, J. et al. Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis. Antimicrob. Agents Chemother. 63, 1\u201314 (2019).","DOI":"10.1128\/AAC.00021-19"},{"key":"35730_CR31","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1128\/AAC.00515-06","volume":"51","author":"R Beer","year":"2007","unstructured":"Beer, R. et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob. Agents Chemother. 51, 379\u2013382 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"35730_CR32","first-page":"523","volume":"62","author":"OW Akkerman","year":"2016","unstructured":"Akkerman, O. W. et al. Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis. Clin. Infect. Dis. 62, 523\u2013524 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"35730_CR33","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/jac\/dkac067","volume":"77","author":"CM Upton","year":"2022","unstructured":"Upton, C. M. et al. Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). J. Antimicrob. Chemother. 77, 1720\u20131724 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"35730_CR34","doi-asserted-by":"publisher","first-page":"6297","DOI":"10.1128\/AAC.02784-14","volume":"58","author":"F Sun","year":"2014","unstructured":"Sun, F. et al. Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis. Antimicrob. Agents Chemother. 58, 6297\u20136301 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"35730_CR35","doi-asserted-by":"crossref","unstructured":"Tucker, E. W. et al. Delamanid central nervous system pharmacokinetics in tuberculous meningitis in rabbits and humans. Antimicrob. Agents Chemother. 63, 1\u201311 (2019).","DOI":"10.1128\/AAC.00913-19"},{"key":"35730_CR36","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1517\/17425255.2013.786042","volume":"9","author":"G Lappin","year":"2013","unstructured":"Lappin, G., Noveck, R. & Burt, T. Microdosing and drug development: past, present and future. Expert Opin. Drug Metab. Toxicol. 9, 817\u2013834 (2013).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"35730_CR37","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41573-020-0080-x","volume":"19","author":"T Burt","year":"2020","unstructured":"Burt, T. et al. Phase 0\/microdosing approaches: time for mainstream application in drug development? Nat. Rev. Drug Disco. 19, 801\u2013818 (2020).","journal-title":"Nat. Rev. Drug Disco."},{"key":"35730_CR38","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1128\/AAC.01644-12","volume":"56","author":"EA Weinstein","year":"2012","unstructured":"Weinstein, E. A. et al. Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected mice. Antimicrob. Agents Chemother. 56, 6284\u20136290 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"35730_CR39","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1128\/AAC.00912-12","volume":"56","author":"IM Rosenthal","year":"2012","unstructured":"Rosenthal, I. M. et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob. Agents Chemother. 56, 4331\u20134340 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"35730_CR40","doi-asserted-by":"crossref","unstructured":"Bigelow, K. M., Tasneen, R., Chang, Y. S., Dooley, K. E. & Nuermberger, E. L. Preserved efficacy and reduced toxicity with intermittent linezolid dosing in combination with bedaquiline and pretomanid in a murine tuberculosis model. Antimicrob. Agents Chemother. 64, 1\u201313 (2020).","DOI":"10.1128\/AAC.01178-20"},{"key":"35730_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223\u2013227 (2005).","journal-title":"Science"},{"key":"35730_CR42","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1128\/AAC.01691-15","volume":"60","author":"R Tasneen","year":"2016","unstructured":"Tasneen, R. et al. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 60, 270\u2013277 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"35730_CR43","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1128\/AAC.04180-14","volume":"59","author":"AA Ordonez","year":"2015","unstructured":"Ordonez, A. A. et al. Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice. Antimicrob. Agents Chemother. 59, 642\u2013649 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"35730_CR44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1021\/acsinfecdis.5b00127","volume":"2","author":"SM Irwin","year":"2016","unstructured":"Irwin, S. M. et al. Bedaquiline and pyrazinamide treatment responses are affected by pulmonary lesion heterogeneity in mycobacterium tuberculosis infected C3HeB\/FeJ Mice. ACS Infect. Dis. 2, 251\u2013267 (2016).","journal-title":"ACS Infect. Dis."},{"key":"35730_CR45","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1128\/AAC.00451-06","volume":"50","author":"E Nuermberger","year":"2006","unstructured":"Nuermberger, E. et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 50, 2621\u20132625 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"35730_CR46","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1093\/infdis\/jiaa016","volume":"223","author":"KM Bigelow","year":"2021","unstructured":"Bigelow, K. M. et al. Pharmacodynamic correlates of linezolid activity and toxicity in murine models of tuberculosis. J. Infect. Dis. 223, 1855\u20131864 (2021).","journal-title":"J. Infect. Dis."},{"key":"35730_CR47","first-page":"96","volume":"65","author":"KE O\u2019Connell","year":"2015","unstructured":"O\u2019Connell, K. E. et al. Practical murine hematopathology: a comparative review and implications for research. Comp. Med. 65, 96\u2013113 (2015).","journal-title":"Comp. Med."},{"key":"35730_CR48","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.2147\/DDDT.S281639","volume":"15","author":"SL Stancil","year":"2021","unstructured":"Stancil, S. L., Mirzayev, F. & Abdel-Rahman, S. M. Profiling pretomanid as a therapeutic option for TB infection: evidence to date. Drug Des. Dev. Ther. 15, 2815\u20132830 (2021).","journal-title":"Drug Des. Dev. Ther."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35730-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35730-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35730-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T08:08:37Z","timestamp":1672301317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35730-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["35730"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-35730-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1999411\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"25 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7974"}}